BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Rituximab: trial readouts and FDA decisions

5 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Karyopharm Therapeutics Inc, Novartis Pharmaceuticals, LaNova Medicines Limited, Epizyme, Inc., Acerta Pharma BV, Loxo Oncology, Inc., Incyte Corporation, Celgene. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2/P3Karyopharm Therapeutics Inc KPTIQNCT04442022 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRelapsed/Refractory Diffuse Large B-cell Lymphomaactive not recruiting501
2026-12-30 est.P2Novartis Pharmaceuticals NVSNCT06388941 Iptacopan in Patients With ANCA Associated VasculitisAnti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitisactive not recruiting84
2027-01-11 est.P1/P2LaNova Medicines LimitedNCT05615974 A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant TumorsMalignant Tumorsrecruiting139
2027-02-13 est.P3Epizyme, Inc.NCT04224493 A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo inRelapsed/Refractory Follicular Lymphoma; Follicular Lymphoma; Refractory Follicular Lymphomaactive not recruiting599
2027-02-15 est.P3Acerta Pharma BVNCT02972840 A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLLymphoma, Mantle Cellactive not recruiting635

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10 est.P3Loxo Oncology, Inc.NCT04965493 A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphomaactive not recruiting600
2026-09-01 est.P3Incyte Corporation INCYNCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsDiffuse Large B-cell Lymphomaactive not recruiting899
2026-06-19P2CelgeneNCT06425302 A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaLymphoma, Follicularactive not recruiting95
2026-06-03P3Hoffmann-La RocheNCT04712097 A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Relapsed or Refractory Follicular Lymphomaactive not recruiting478

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.